Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate

Financial Performance - Immatics N.V. reported revenue of $56.8 million for the year ended December 31, a significant decrease from $183.1 million in 2024, attributed to a one-time non-cash revenue from a deal with Bristol Myers Squibb in 2024 [3] - The company posted a net loss of $230.8 million in 2025, contrasting with a net profit of $17.9 million in 2024, primarily due to lower non-cash revenue and increased costs related to clinical program advancements [4] Business Updates - The Phase 3 SUPRAME trial for the drug candidate anzu-cel (IMA203) is ongoing, with strong enrollment rates. This trial focuses on the efficacy, safety, and tolerability of the drug for patients with specific types of melanoma [5] - Immatics anticipates beginning final analyses of the study data later in 2026 and aims to seek marketing approval for anzu-cel in the first half of 2027, with a product launch expected in the second half of 2027 [5] Financial Position - At the end of the quarter, Immatics N.V. had $551.4 million in cash and other financial assets, indicating a strong liquidity position for ongoing and future operations [6]